Radiation Post-CAR T in Refractory Lymphoma

Hematologic Malignancy Clinical Trial

Official title: Radiation Therapy To Enhance CAR T Efficacy Early in Post-CAR T Cell Therapy Refractory Lymphoma: A Pilot Study

Status Terminated

Clinical Trial Summary

This study is evaluating the safety and efficacy of using radiotherapy in participants who have refractory lymphoma shortly after receiving CAR T cell therapy (axicel or tisacel).

Clinical Trial Description

This research study is a Pilot Study, which is the first time investigators are examining this intervention after administration of CAR T cell therapy. This research study looks to systematically investigate the safety and efficacy of radiotherapy following CAR T cell therapy (axicel or tisacel) in refractory lymphoma. CAR T cell therapy involves genetically modifying T cells to target tumor cells for death. Radiotherapy is a standard treatment offered with refractory lymphoma and uses high-energy x rays, or particles, to destroy or damage cancer cells. Few have received CAR T cell therapy prior to radiation therapy and this study aims to gather more information on radiotherapy following CAR T cell therapy as a treatment option and its potential to improve participants immune system's response to cancer cells as well as its interaction with CAR T cell therapy to better treat refractory lymphoma.

The research study procedures include screening for eligibility, enrollment, biopsy following radiation, post-treatment period, and long-term follow-up.

• Participants will receive radiotherapy at a dose and schedule determined by the study doctor.

• Participants will be followed for up to 24 months after completion of study treatment.

It is expected that about 20 people will take part in this research study. ;

Related Conditions & MeSH terms

• Hematologic Malignancy
• Hematologic Neoplasms
• Lymphoma
• Neoplasms
• Refractory Lymphoma

• NCT number: NCT04473937
• Study type: Interventional
• Source: Massachusetts General Hospital
• Status: Terminated
• Phase: N/A
• Start date: January 5, 2021
• Completion date: July 3, 2023